-

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

  • Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)
  • Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.”

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL):

ACCESS HERE THE FULL PRESS RELEASE

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Industry:

Medincell

BOURSE:MEDCL
Release Versions
English

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

More News From Medincell

Medincell: Publication of the 2026 Financial Calendar

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Event Date Annual results 2025-2026 (April 2025-March 2026) Tuesday, June 16, 2026 General Meeting Thursday, September 10, 2026 Half-Year results 2026-2027 (April-September 2026) Tuesday, December 8, 2026 About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are design...

Medincell Publishes its Consolidated Half-Year Financial Results

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): “We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leading...

Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population2 Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia2 Teva press release: https://ir.tevapharm.com/news-and-events/press-re...
Back to Newsroom